Results 31 to 40 of about 323,501 (341)

Investigating lupus retention in care to inform interventions for disparities reduction: an observational cohort study. [PDF]

open access: yes, 2020
BACKGROUND:Systemic lupus erythematous (SLE) disproportionately impacts patients of color and socioeconomically disadvantaged patients. Similar disparities in HIV were reduced through a World Health Organization-endorsed Care Continuum strategy targeting
Ahmad, Umber   +8 more
core  

The significance of M1/M2 macrophage-like monocytes in children with systemic lupus erythematosus

open access: yesEuropean Journal of Inflammation, 2019
Monocytes/macrophages are important in the development of systemic lupus erythematosus. To research M1 and M2 macrophage-like monocytes in the peripheral blood of children with systemic lupus erythematosus and explore the clinical significance, M1 and M2
Xiao-Ling Niu   +6 more
doaj   +1 more source

Age-related changes in Serum Growth Hormone, Insulin-like Growth Factor-1 and Somatostatin in System Lupus Erythematosus

open access: yesBMC Musculoskeletal Disorders, 2004
Background Systemic lupus erythematosus is an age- and gender-associated autoimmune disorder. Previous studies suggested that defects in the hypothalamic/pituitary axis contributed to systemic lupus erythematosus disease progression which could also ...
Malemud Charles J, Denko Charles W
doaj   +1 more source

A Toll for lupus [PDF]

open access: yes, 2005
Toll-like receptor (TLR)-9 recognizes CpG motifs in microbial DNA. TLR9 signalling stimulates innate antimicrobial immunity and modulates adaptive immune responses including autoimmunity against chromatin, e.g., in systemic lupus erythematosus (SLE ...
Anders HJ, H-J Anders, Stacey KJ
core   +1 more source

Belimumab : a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis [PDF]

open access: yes, 2013
Objectives: To undertake a systematic review and meta-analysis to investigate clinical effectiveness of belimumab for patients with systemic lupus erythematosus (SLE) and antinuclear and/or anti-double-stranded DNA (dsDNA) autoantibodies.
Clarke, Aileen   +9 more
core   +1 more source

Fibrous histiocytoma as first presentation in systemic lupus erythematosus and sero-positive Sjögren's syndrome

open access: yesAmerican Journal of Ophthalmology Case Reports, 2018
Purpose: To describe a triad of fibrous histiocytoma, Systemic Lupus Erythematosus and Sero-positive Sjögren's Syndrome. Observations: This case was diagnosed first as bilateral fibrous histiocytoma of cheeks, which on further investigations proved to be
Abdullah Al-Mujaini   +2 more
doaj   +1 more source

Serological comparison of systemic lupus erythematosus with neuropsychiatric lupus using synthetic nucleic acid antigens

open access: yesJournal of Translational Autoimmunity, 2020
Neuropsychiatric systemic lupus erythematosus is an autoimmune disorder characterized by an irregular exchange between the central nervous system and the immune system, leading to the outbreak of neurological conditions with possible disabling effects ...
Sangita Khatri   +7 more
doaj   +1 more source

Systemic 5-fluorouracil induced lupus erythematosus: a review of the literature [PDF]

open access: yes, 2019
Drug-induced subacute cutaneous lupus erythematosus (SCLE) is the most common subtype of drug-induced systemic lupus erythematosus and has been associated with more than 100 drugs.
Marsch, Amanda F, Shakhbazova, Anastasia
core  

Role of brain perfusion SPECT with 99mTc HMPAO in the assessment of response to drug therapy in patients with autoimmune vasculitis: a prospective study [PDF]

open access: yes, 2015
BACKGROUND: The diagnosis of vasculitis in the brain remains a quite difficult achievement. To the best of our knowledge, there is no imaging method reported in literature which is capable of reaching to a diagnosis of vasculitis with very high ...
Anna Margherita Maffione, 2   +11 more
core   +1 more source

Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective We report the 12‐month follow‐up outcomes from a Phase 2 clinical trial (NCT04146051) evaluating Descartes‐08, a BCMA‐directed RNA chimeric antigen receptor T‐cell (rCAR‐T) therapy for refractory generalized myasthenia gravis (MG).
Nizar Chahin   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy